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Abstract
Background
The case-fatality rate of severe leptospirosis can exceed 50%. While prompt supportive
care can improve survival, predicting those at risk of developing severe disease is challeng-
ing, particularly in settings with limited diagnostic support.
Methodology/Principal findings
We retrospectively identified all adults with laboratory-confirmed leptospirosis in Far North
Queensland, Australia, between January 1998 and May 2016. Clinical, laboratory and radio-
logical findings at presentation were correlated with the patients’ subsequent clinical course.
Medical records were available in 402 patients; 50 (12%) had severe disease. The presence
of oliguria (urine output�500 mL/24 hours, odds ratio (OR): 16.4, 95% confidence interval
(CI): 6.9–38.8, p<0.001), abnormal auscultatory findings on respiratory examination (OR
11.2 (95% CI: 4.7–26.5, p<0.001) and hypotension (systolic blood pressure�100 mmHg,
OR 4.3 (95% CI 1.7–10.7, p = 0.002) at presentation independently predicted severe dis-
ease. A three-point score (the SPiRO score) was devised using these three clinical vari-
ables, with one point awarded for each. A score could be calculated in 392 (98%) patients;
the likelihood of severe disease rose incrementally: 8/287 (3%), 14/70 (20%), 18/26 (69%)
and 9/9 (100%) for a score of 0, 1, 2 and 3 respectively (p = 0.0001). A SPiRO score <1 had
a negative predictive value for severe disease of 97% (95% CI: 95–99%).
Conclusions/Significance
A simple, three-point clinical score can help clinicians rapidly identify patients at risk of
developing severe leptospirosis, prompting early transfer to referral centres for advanced
supportive care. This inexpensive, bedside assessment requires minimal training and may
have significant utility in the resource-limited settings which bear the greatest burden of
disease.
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Author summary
Leptospirosis, a neglected tropical disease with a global distribution, is estimated to kill
60,000 people every year. Predicting those at risk of developing severe disease is challeng-
ing, and a simple scoring system to quantify the risk of severe disease has proven elusive.
Identifying the high-risk patient is important, as it might expedite the initiation of life-sav-
ing supportive care. This review of 402 adult patients with leptospirosis in tropical Austra-
lia determined that three clinical variables identified at presentation independently
predicted severe disease (a subsequent requirement for Intensive Care Unit admission,
intubation, vasopressor support, renal replacement therapy or the development of pulmo-
nary haemorrhage). These three variables (abnormal auscultatory findings on respiratory
examination, hypotension and oliguria) were used to generate a simple, three-point clini-
cal score which can be determined rapidly and reliably at the bedside by health care work-
ers with minimal training. This simple score may help the clinical management of
patients with leptospirosis, particularly in lower and middle-income countries that bear
the greatest burden of disease.
Introduction
Leptospirosis is a zoonotic infection with a global distribution [1, 2]. Although most infections
are mild and self-limiting, the disease is believed to kill almost 60,000 people every year [1].
Severe disease–manifesting as pulmonary haemorrhage, acute kidney injury (AKI) or multior-
gan failure–develops in 5–15% of cases. The case-fatality rate of severe leptospirosis is as low as
6% if there is prompt access to vasopressors, renal replacement therapy (RRT) and mechanical
ventilation [3], but it can rise to greater than 50% if the delivery of this supportive care is
delayed [4].
However, identifying the patients who are at risk of developing severe disease can be diffi-
cult. Different studies have suggested that the presence of a variety of clinical features, labora-
tory investigations and imaging and electrocardiography findings can help [5–10]. While these
approaches may be helpful in well-resourced settings where there is access to advanced labora-
tory and radiology support, they may have less utility in low and middle-income countries
(LMIC), which bear a disproportionate burden of the disease [1].
Leptospirosis is endemic in tropical northern Australia, and the state of Queensland has
one of the highest reported incidences in the developed world [11]. Most of the cases in
Queensland occur in relatively remote locations where there is limited access to diagnostic
support. Accordingly, given the potential for patient deterioration, if there is clinical uncer-
tainty about a patient’s prognosis, they are often transferred–sometimes great distances–to a
tertiary centre for continuing care. Not only is this frequently unnecessary, it is inconvenient
for patients and their families, and expensive for the health system.
To improve the triage of patients with leptospirosis, and identify patient characteristics that
predict severe disease, we reviewed the presentation of adults with confirmed leptospirosis in
Far North Queensland and correlated their clinical findings and laboratory and imaging
results with their subsequent clinical course. Our aim was to produce a simple score that could
be used to quickly identify the patients at greatest risk of deterioration, expediting their referral
for intensive care unit (ICU) support. We also hoped that the score could predict which
patients could be safely managed without transfer, providing reassurance for local clinicians
and reducing costs for the health system. Recognising that leptospirosis has a significant
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burden in LMIC–and in remote locations in high-income countries–it was also hoped that the
score that might be applicable where access to diagnostic support is limited.
Methods
Study population and data collection
This retrospective study was performed at Cairns Hospital, a 531-bed, tertiary referral hospital
in tropical, northern Australia that–with 16 smaller community hospitals–provides medical
services to a population of approximately 280,000 people across an area of 380,000km2. The
local electronic pathology reporting system (AUSLAB) was used to identify all leptospirosis
cases in the region between January 1998 and May 2016.
Adult patients (�16 years of age) were defined as having confirmed leptospirosis if they
met one or more of the following criteria: (1) Leptospires isolated from blood culture; (2)
Microscopic agglutination test (MAT) single titre of� 1:400; (3) Fourfold rise in MAT anti-
body titres; (4) Detection of Leptospira in blood by polymerase chain reaction (PCR).
Medical charts were reviewed at the hospital of first presentation and at Cairns Hospital if a
patient required inter-hospital transfer. It was recognized that a proportion of the medical rec-
ords would be unavailable as the health service has a policy of destroying the paper medical
record if there have been no new patient encounters for ten years.
Patient characteristics at the time of presentation to medical attention were reviewed. The
World Health Organization was undertaking enhanced surveillance of leptospirosis in the
region and a case report form was in use for much of the study period. Clinical findings, hae-
matology, biochemistry, urinalysis, chest x-ray and electrocardiogram results were recorded.
The following cut-offs–based on the literature, reference ranges and everyday clinical prac-
tice–were used to characterise any association severe disease: hypotension (systolic blood pres-
sure�100 mmHg), anaemia (haemoglobin�100 g/L), severe thrombocytopenia (platelets
�50 x 109/L), acidosis (bicarbonate�22 mmol/L), AKI (creatinine�2 mg/dL), jaundice
(bilirubin�3 mg/dL) and C-reactive protein�200 mg/L. The quick Sequential Organ Failure
Assessment (qSOFA) and the quick National Early Warning Score (qNEWS) scores were cal-
culated for the patients with sufficient clinical information [12, 13].
Outcome
Severe disease was defined as the development of pulmonary haemorrhage, ICU admission, or
a requirement for RRT, intubation or vasopressor support. Pulmonary haemorrhage was said
to be present if there was frank haemoptysis or if blood was present on tracheal aspirate.
Ethical considerations
The study obtained approval from the Far North Queensland Human Research Ethics Com-
mittee (HREC/16/QCH/37 – 1043LR). As per the approval, this retrospective study used anon-
ymized patient data and did not obtain individual patient consent. This study reviewed human
patients only; no animals were involved in any aspect of the study.
Statistical analysis
Data were entered into an electronic database (Microsoft Excel) and analysed using statistical
software (Stata 14.0). Groups were analysed using the Kruskal-Wallis and chi-squared tests.
Multivariate analysis was performed using backwards linear and logistic regression. For the
multivariate analysis, only variables with an area under the receiver operating characteristic
(AUROC) curve of>0.7 in univariate analysis were selected.
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Results
There were 738 cases of laboratory-confirmed leptospirosis during the study period. Medical
charts were available in 429 cases; 402 (94%) were adults. Their median (interquartile range
(IQR)) age was 33 (23–45) years; 362 (90%) were male. Nearly all the cases (397/402 (99%))
were acquired locally, 273/397 (69%) occurred during the region’s November-April wet sea-
son, and 355/397 (89%) occurred in a region of high-intensity banana and dairy cattle farming
situated approximately 100km south of Cairns. In the 384 in whom an occupation was docu-
mented, 327 (85%) had the potential for occupational exposure. There were 50 (12%) patients
who developed severe disease, including two (0.5%) who died (Fig 1).
In 331/402 (82%) cases, clinicians included leptospirosis in the differential diagnosis at the
time of presentation. Leptospires were isolated from blood culture in 275/402 (68%), MAT
was diagnostic in 178/402 (44%) and PCR was positive in 151/402 (38%). Serovars could be
Fig 1. Consort diagram illustrating the number of confirmed cases of leptospirosis in Far North Queensland,
Australia between 1998 and 2016.
https://doi.org/10.1371/journal.pntd.0007205.g001
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determined in 353/402 (88%); Australis and Zanoni were the commonest serovars, and the
most likely to cause severe disease (Table 1).
The median (IQR) duration of symptoms was 4 (3–6) days in the patients who developed
severe disease compared with 3 (2–4) days in those that did not (p = 0.0001). Comorbidities
were documented in 395 patients and were more common in the patients who had severe dis-
ease (15/49 (31%) than those that did not (29/346 (8%), p<0.0001).
Clinical findings were similar to those in the published literature, although only 9% had a
serum bilirubin�3mg/dL and conjunctival suffusion was documented in only 109/397 (27%)
who were assessed. The symptoms, signs and laboratory tests and their association with severe
disease are presented in Tables 2 and 3. In univariate analysis, the symptoms of diarrhoea, dys-
pnoea and bleeding were most associated with the development of severe disease (Table 2).
The presence of renal impairment and thrombocytopenia were the laboratory tests most asso-
ciated with the development of severe disease (Table 3).
In the 50 patients with severe disease, 45 (90%) required ICU admission, 27 (54%) devel-
oped pulmonary haemorrhage, 27 (54%) required vasopressor support, 18 (36%) required
RRT and 24 (48%) required mechanical ventilation. APACHE III scores were available for 39/
45 (87%) patients admitted to ICU; the median score was 84 (range 27–169).
Table 1. Commonest serovars causing leptospirosis in Far North Queensland, Australia between 1998 and 2016.
Serovar N Non-severe disease Severe disease
Zanoni 121 104 (86%) 17 (14%)
Australis 80 62 (78%) 18 (22%)
Arborea 57 57 (100%) 0 (0%)
Kremastos 25 23 (92%) 2 (8%)
Hardjo 20 17 (85%) 3 (15%)
Robinsoni 15 14 (93%) 1 (7%)
Szwajizak 12 12 (100%) 0 (0%)
https://doi.org/10.1371/journal.pntd.0007205.t001
Table 2. Presenting symptoms and signs of non-severe and severe leptospirosis.
N Non-severe disease
n = 352
Severe disease
n = 50
p AUROC
Bleeding 397 7 (2%) 20 (41%) <0.0001 0.69 (0.62–0.76)
Diarrhoea 398 79 (22%) 24 (49%) <0.0001 0.63 (0.56–0.71)
Dyspnoea 397 14 (4%) 12 (24%) <0.0001 0.60 (0.54–0.66)
Hepatomegaly 396 15 (4%) 10 (20%) <0.0001 0.58 (0.52–0.64)
Abdominal pain 398 75 (21%) 17(35%) 0.04 0.57 (0.50–0.64)
Nausea/vomiting 398 238 (68%) 39 (80%) 0.10 0.56 (0.49–0.62)
Cough 397 97 (28%) 20 (41%) 0.06 0.56 (0.49–0.64)
Rash 397 19 (5%) 5 (10%) 0.19 0.52 (0.48–0.57)
Jaundice 396 9 (3%) 3 (6%) 0.18 0.52 (0.48–0.55)
Fevers/chills/sweats 397 337 (97%) 47 (96%) 0.74 0.50 (0.47–0.52)
Back pain 396 85 (25%) 11 (22%) 0.75 0.49 (0.43–0.55)
Arthralgia/myalgia 397 291 (84%) 39 (80%) 0.48 0.48 (0.42–0.54)
Conjunctival suffusion 397 98 (28%) 11 (22%) 0.40 0.47 (0.41–0.54)
Lymphadenopathy 397 25 (7%) 1 (2%) 0.17 0.47 (0.45–0.50)
Headache 397 291 (84%) 35 (71%) 0.037 0.44 (0.37–0.51)
https://doi.org/10.1371/journal.pntd.0007205.t002
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There were only two deaths in the study. The first was an 80-year-old man with a history of
diabetes mellitus and 5 days of symptoms; he developed multiorgan failure and died one day
after presentation despite ICU support. The second, a 73-year-old man with a history of car-
diovascular disease, chronic lung disease and connective tissue disease, had four days of symp-
toms; he also had multiorgan failure and died within one day of presentation.
Multivariate analysis identified four independent variables associated with severe disease;
three of these variables were clinical signs–abnormal auscultatory findings on respiratory
examination (odds ratio (OR) (95% CI): 8.9 (3.5–22.4), p<0.0001), oliguria (OR (95% CI): 8.2
(3.2–21.2) p<0.0001) and hypotension (OR (95% CI): 3.8 (1.5–9.9), p = 0.006) and one was a
laboratory variable (creatinine�2 mg/dL) (OR (95% CI): 7.0 (2.7–18.1) p<0.0001). The three
clinical findings–awarded one point each–were used to generate a three-point SPiRO score
(Systolic blood Pressure�100 mmHg, Respiratory auscultation abnormalities, Oliguria,
Table 4). The risk of severe disease increased incrementally with the SPiRO score. A score of
Table 3. Features of leptospirosis at presentation and their association with subsequent severe disease.
Variable N Non-severe disease
n = 352
Severe disease
n = 50
p AUROC
Age (years) 402 31 (23–42) 48 (34–61) 0.0001 0.74 (0.67–0.81)
Days of symptoms 390 3 (2–4) 4 (3–6) 0.0001 0.77 (0.71–0.84)
Abnormal respiratory auscultation 397 22 (6%) 28 (57%) <0.0001 0.75 (0.68–0.85)
Oliguria 397 19 (5%) 29 (59%) <0.0001 0.77 (0.70–0.84)
Systolic blood pressure (mmHg) 393 120 (110–130) 100 (90–116) 0.0001 0.73 (0.64–0.81)
Hemoglobin (g/L) 390 146 (138–154) 130 (117–147) 0.0001 0.73 (0.64–0.82)
WBC (x 109/L) 387 8.7 (6.5–10.7) 10 (8.4–13.9) 0.0002 0.67 (0.59–0.75)
Neutrophils (x 109/L) 387 7.5 (5.2–9.4) 8.9 (7.2–12.5) 0.0001 0.67 (0.59–0.75)
Platelets (x 109/L) 370 154 (123–194) 97 (54–146) 0.0001 0.75 (0.66–0.83)
Sodium (mmol/L) 393 135 (132–136) 132 (128–135) 0.0001 0.67 (0.58–0.75)
Potassium (mmol/L) 378 3.7 (3.5–4.0) 3.6 (3.3–4.1) 0.12 0.57 (0.47–0.67)
Bicarbonate (mmol/L) 387 25 (23–26) 22 (20–25) 0.0001 0.71 (0.62–0.80)
Urea (mg/dL) 391 14.6 (11.8–18.5) 33.9 (20.4–60.8) 0.0001 0.85 (0.78–0.91)
Creatinine (mg/dL) 391 1.1 (0.9–1.3) 2.3 (1.4–4.8) 0.0001 0.86 (0.81–0.92)
Glucose (mg/dL) 207 117 (108–130) 123 (101–144) 0.15 0.58 (0.45–0.71)
Bilirubin (mg/dL) 386 0.9 (0.7–1.3) 1.2 (0.9–1.9) 0.0001 0.70 (0.63–0.78)
ALT (U/L) 385 32 (21–65) 46 (27–74) 0.01 0.61 (0.53–0.68)
LDH (U/L) 169 248 (206–317) 279 (214–376) 0.07 0.61 (0.49–0.73)
Creatine kinase (U/L) 43 130 (50–448) 505 (125–860) 0.03 0.70 (0.54–0.86)
Prothrombin time (s) 73 13 (11–14) 14 (12–15) 0.17 0.59 (0.46–0.73)
Lactate (mmol/L) 42 1.0 (0.8–2.0) 2.0 (1.1–5.8) 0.02 0.72 (0.56–0.88)
C-reactive protein 123 183 (100–257) 309 (233–335) 0.0001 0.78 (0.67–0.88)
CXR abnormal 154 16 (15%) 29 (62%) <0.0001 0.73 (0.66–0.81)
Abbreviations: AUROC, Area under receiver operating curve; WBC, White blood cells; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CXR, Chest X-ray
https://doi.org/10.1371/journal.pntd.0007205.t003
Table 4. The SPiRO score for predicting severe leptospirosis.
Clinical feature
Systolic blood Pressure�100 mmHg 1 point
Respiratory auscultation abnormalities 1 point
Oliguria 1 point
https://doi.org/10.1371/journal.pntd.0007205.t004
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zero had a negative predictive value (NPV) for severe disease of 97.2% (95% CI: 94.6–98.8%).
A score greater than one had a positive predictive value (PPV) (95% CI) for severe disease of
77.1% (59.9–89.6), while a score of three had a PPV of 100% (66.4–100) (Table 5 and Fig 2).
The predictive ability of the SPiRO score was compared with the qSOFA and the qNEWS
scores. In the 379/402 (94%) patients in whom the scores could be calculated, the AUROC
of the SPiRO score (0.87 (95% CI 0.81–0.9) was higher than that of the qSOFA (0.76 (95% CI
0.70–0.83) score (p = 0.003). The difference between the AUROC of the SPiRO score and the
qNEWS score (0.81 (95% CI 0.74–0.87) failed to reach statistical significance (p = 0.053).
Discussion
In adults with leptospirosis, a simple three-point clinical score–the SPiRO score–appears to
reliably identify patients at risk of severe disease. The score could be used anywhere that lepto-
spirosis is seen, but as a rapid and inexpensive assessment, which can be performed at the bed-
side by even junior health care workers, it has significant appeal for a disease that has its
greatest impact in resource-poor settings. An absence of hypotension, oliguria or abnormal
auscultatory findings–a SPiRO score of zero–was particularly helpful in identifying low-risk
Table 5. Ability of the SPiRO score at presentation to predict severe leptospirosis at different cut-offs.
0 1 2 3
Number of with severe disease/number of cases (%) 8/287 (3%) 14/70 (20%) 18/26 (69%) 9/9 (100%)
Sensitivity % (95% CI) - 84% (70–93) 55% (40–69) 18% (9–32)
Specificity % (95% CI) - 81% (77–85) 98% (96–99) 100% (99–100)
Positive predictive value % (95% CI) - 39% (30–49) 77% (60–90) 100% (66–100)
Negative predictive value % (95% CI) - 97% (95–99) 94% (91–96) 90% (86–92)
https://doi.org/10.1371/journal.pntd.0007205.t005
Fig 2. Positive predictive value of developing severe leptospirosis using the three-point SPiRO score calculated at presentation.
https://doi.org/10.1371/journal.pntd.0007205.g002
Predicting severe leptospirosis
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007205 February 13, 2019 7 / 13
patients. The score could therefore determine which patients can be safely managed in remote
locations, avoiding unnecessary and expensive transfer. The likelihood of severe disease rose
incrementally as the score increased, facilitating recognition of the high-risk patient, expedit-
ing the initiation of supportive treatment and prompting consideration of transfer to referral
centres.
Although many variables have been shown to predict severe leptospirosis, a simple scoring
system to quantify the relative risk of severe disease has proven elusive [5]. As in this series,
older age has been associated with severe leptospirosis and worse outcomes in multiple coun-
tries including India [4], Brazil [14] and Turkey [15]. Other predictors of severe leptospirosis
or leptospirosis-attributable mortality have consisted of a combination of clinical features, lab-
oratory findings and interpretation of imaging and electrocardiography. It is notable that pul-
monary involvement is associated with worse outcomes in almost every published series, while
renal involvement and hypotension also have also been shown to have significant prognostic
utility.
In the French West Indies, dyspnoea, oliguria, white blood cell count>12,900/mm3, alveo-
lar infiltrates on chest X-rays and repolarization abnormalities on electrocardiograms were
independently associated with death [10]. In Brazil, pulmonary involvement, oliguria, creati-
nine>3 mg/dL and platelets<70,000/mm3 were independent predictors of mortality, with
pulmonary involvement being the strongest prognostic factor [16]. Similarly, in India [17, 18],
Indonesia [19], and Greece [20], pulmonary involvement was associated with increased mor-
tality. In Thailand, pulmonary rales, oliguria, hypotension and hyperkalaemia were all inde-
pendently associated with death [21].
While an elevated serum creatinine, white cell count and thrombocytopenia were also asso-
ciated with severe disease in our series, it is important to remember that laboratory support
may be limited in the rural and remote settings of LMIC where most cases of leptospirosis are
seen. Even where there is access to laboratory support in these locations, results are not always
available promptly. Similarly, while an abnormal chest X-ray had prognostic utility in our
series, there may not be access to radiology support in leptospirosis-endemic areas and even
when there is, accurate interpretation of imaging findings requires high quality images and sig-
nificant medical training. Finally, although electrocardiography is inexpensive and relatively
easy to perform, the identification of repolarization abnormalities also requires some
expertise.
These issues may also be relevant in high-income settings like Australia. In rural locations
where most cases of leptospirosis are diagnosed, it can take up to 24 hours for the processing,
transport and analysis of even simple haematology and biochemistry tests such as platelet
count or serum creatinine. Other laboratory tests that have been linked to severe leptospirosis,
such as the quantification of leptospires in blood, are unlikely to be routinely available in the
foreseeable future [6, 22, 23]. Imaging is also not necessarily accessible, and patients are usually
reviewed initially by junior staff.
The entirely clinical SPiRO score therefore has significant appeal. It is simple to perform,
reproducible, requires little medical training and addresses the renal impairment, pulmonary
involvement and hypotension that have repeatedly been shown to be associated with the worst
clinical outcomes [10, 16–21]. AKI in leptospirosis occurs due to direct leptospire invasion
resulting in tubulointerstitial nephritis [24]. Renal biopsy most frequently reveals a mononu-
clear cellular infiltration and interstitial oedema, although an immune-complex glomerulone-
phritis may also be present [25, 26]. While leptospirosis has traditionally been thought to cause
non-oliguric AKI [27], oliguria is an early clinical marker of AKI that is less likely to respond
to rehydration and more likely to require RRT [28]. Hypotension in leptospirosis is usually
due to vasodilatory mediators and proinflammatory cytokines released in response to the
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infection; this results in reduced renal blood flow, further exacerbating renal injury [29]. Pul-
monary involvement–perhaps the most serious manifestation of severe disease–is frequently
overlooked [23, 30]. Leptospirosis impairs the fluid handling of alveolar epithelial cells result-
ing in pulmonary oedema which can trigger acute respiratory distress syndrome [31–33]. Pul-
monary haemorrhage–the most feared respiratory manifestation–is thought to occur from a
direct effect of leptospiral proteins or toxic cellular components on multiple components of
the alveolocapillary membrane [34]. As larger areas of haemorrhage coalesce, symptoms
worsen and clinical signs are more likely to be apparent on auscultation [35]. As pulmonary
haemorrhage progresses, pulmonary vascular resistance also increases, further contributing to
systemic hypotension [29].
Severe disease was common in our series, but the case-fatality rate was very low with both
deaths occurring in elderly patients with significant comorbidities. The wide variation in case-
fatality rates reported in the literature has been attributed to differing definitions of severe lep-
tospirosis, although our definition was conservative and the patients’ APACHE III scores were
high. It is possible that the local case-fatality rate is higher than we have reported as patients
with rapidly fatal leptospirosis may have a negative MAT test early in their disease. However,
culture and PCR are used widely locally with only 18% of cases were diagnosed by MAT alone
and accordingly, the number of unrecognized, fatal cases is probably small. The excellent out-
comes are likely to be the result of early disease recognition and access to prompt ICU support.
There is an extensive medical retrieval network in Australia which ensures people living in
rural and remote services have access to sophisticated healthcare. However, given the country’s
great expanse, these services are costly, frequently relying on a combination of road ambu-
lances, helicopters and aeroplanes. While the coordination of retrieval services is centralised
and efficient, organising safe and appropriate medical evacuation is time-consuming. A simple
scoring system that facilitates recognition of patients with severe leptospirosis could help guide
clinicians to identify which patients are most likely to require critical care support and early
referral to retrieval services. Conversely, the SPiRO score could help prevent unnecessary med-
ical evacuation, which would be welcome for patients and reassuring for the clinicians
involved in their care.
Our study was retrospective and the SPiRO score requires prospective validation to ensure
its applicability in other geographical settings. However, in other locations including Brazil
[14, 36], Thailand [21], Moldova [37], Greece [20], and Re´union [38], hypotension, oliguria or
abnormal respiratory auscultation have been identified previously as independent predictors
of severe disease. Indeed, in a much smaller series from French Polynesia the same three clini-
cal parameters were found to be the only independent variables in predicting severe disease
[39]. The SPiRO score therefore has potential global utility. While many counties with a high
incidence of leptospirosis do not have access to medical retrieval services or advanced ICU
support, the score may still identify those who may benefit from closer monitoring and might
be expected to improve outcomes.
The clinical findings of leptospirosis have been linked to the infecting serovar, with ser-
ogroup Icterohaemorrhagiae particularly associated with severe disease [6, 35]. This serogroup
was uncommon in our series, occurring in only two cases, while severe disease was most com-
monly associated with serovars Australis and Zanoni. Variations in the prevalence of different
serogroups and serovars have the potential to limit the generalizability of our findings, how-
ever, as previously noted, the clinical phenotype seen in our cohort was remarkably similar to
that seen in the published literature [3, 10, 35].
Evidently, the SPiRO score can only be applied to patients with a diagnosis of leptospirosis,
a condition whose prompt diagnosis remains challenging. While clinical findings can inform
the clinician, they are non-specific and may not differentiate leptospirosis from other tropical
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infections including rickettsial disease, malaria and dengue. PCR is rarely available where the
disease is endemic, and even in well-resourced settings like Australia, results take several days.
Point-of-care tests have the greatest potential to facilitate diagnosis in both resource-poor and
rich countries, but although their sensitivity and specificity is improving, these tests are not
currently in routine use [40, 41]. If reliable point-of care tests can be developed and coupled
with a validated simple predictive tool, the early recognition and management of leptospirosis
is likely to improve significantly. That being said, clinicians in leptospirosis-endemic areas
often recognize the disease–in our series, leptospirosis was in the initial differential diagnosis
in over 82% of cases. Furthermore, even when the diagnosis of leptospirosis cannot be con-
firmed, a patient presenting to a remote clinic with hypotension and evidence of pulmonary
and renal disease is likely to require referral for more sophisticated care whatever the aetiology.
The retrospective nature of our study meant that documentation was sometimes incom-
plete, and investigations were not standardised. However, clinicians working in the area have a
high index of suspicion for the disease and a leptospirosis pro forma was in use for most of the
study period. As a result, the clinical features on presentation were generally well documented.
Data are now being collected prospectively to confirm these preliminary observations. The
antibiotic therapy, its timing, route and duration were available in most cases and almost all
patients received at least one appropriate agent. However, the enormous variety of antibiotic
regimens prescribed precluded meaningful analysis of their relative efficacies.
In conclusion, a simple three-point clinical based scoring tool appears to help clinicians
identify people at risk of developing severe leptospirosis. The score requires prospective valida-
tion in other geographical locations, but it has the potential to improve the care of people with
leptospirosis, particularly in resource-limited settings where the disease has its greatest clinical
burden.
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